CPT code 78812 represents FDG positron emission tomography (PET) imaging used to detect metabolic activity consistent with malignancy and to visualize three-dimensional distributions of radiotracer uptake. Nationally, FDG-PET plays a central role in cancer diagnosis, staging, and surveillance because it identifies hypermetabolic lesions that may not be apparent on anatomic imaging alone. The code captures a diagnostic imaging service that informs clinical decision-making across oncology, radiation planning, and systemic therapy assessment.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for PET imaging with FDG, typical sites of service, and the operational implications for providers and imaging centers. The publication also summarizes reimbursement benchmarks, common billing modifiers, and payer coverage considerations where available. Policy updates that affect coverage criteria and utilization management for FDG-PET imaging are highlighted, along with practical notes on documentation elements that support medical necessity. This resource is designed for clinicians, billing professionals, and policy analysts seeking a national perspective on use and billing of FDG-PET imaging under CPT code 78812.